Calidi Biotherapeutics (CLDI) Non-Current Assets (2021 - 2025)

Calidi Biotherapeutics has reported Non-Current Assets for 5 years, with the latest figure at $2.6 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets fell 34.24% year-over-year to $2.6 million; the trailing twelve-month figure through Dec 2025 stood at $12.5 million (down 33.15% YoY), and the FY2025 full-year result was $2.6 million, down 34.24% from the prior year.
• Non-Current Assets for Q4 2025 stood at $2.6 million, down from $3.0 million in the prior quarter.
• The five-year high for Non-Current Assets was $230.3 million in Q4 2021, with the low at $2.6 million in Q4 2025.
• Average Non-Current Assets over 5 years is $53.2 million, with a median of $5.7 million recorded in 2023.
• Peak annual rise in Non-Current Assets reached 30.81% in 2024, while the deepest fall reached 88.88% in 2024.
• Tracing CLDI's Non-Current Assets over 5 years: stood at $230.3 million in 2021, then tumbled by 81.57% to $42.5 million in 2022, then sank by 86.54% to $5.7 million in 2023, then sank by 30.81% to $4.0 million in 2024, then plunged by 34.24% to $2.6 million in 2025.
• The last three Non-Current Assets figures came in at $2.6 million (Q4 2025), $3.0 million (Q3 2025), and $3.3 million (Q2 2025), per Business Quant data.

Peer Comparison